Investigational drug · Phase 3
Iparomlimab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small-cell Lung Cancer, Resectable Locally Advanced Esophageal Squamous Cell Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
155
Any phase or sponsor naming "Iparomlimab"
First trial start
2025
Feb 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Iparomlimab", any sponsor or status.
- Phase 2136
Conditions studied
As listed on its trial records.
- Small-cell Lung Cancer
- Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Iparomlimab" as an intervention, largest first.
- a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.Pivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06789796 · 636 participants (planned) · Start Feb 2025 · Primary completion Mar 2028
Drug: Iparomlimab and Tuvonralimab (QL1706); placebo for QL1604 and 2 more · For: Small-cell Lung Cancer
- QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.Pivotal-lookingRecruiting
Sun Yat-Sen University Cancer CenterAcademic, hospital or other
NCT06749899 · 580 participants (planned) · Start May 4, 2025 · Primary completion Dec 1, 2028
Drug: QL1706; Gemcitabine and 1 more · For: Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer
Sites: Fuzhou, China; Dongguan, China; Foshan, China · 19 sites in all
- QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical CancerPivotal-lookingNot yet recruiting
Fujian Cancer HospitalGovernment (non-federal)
NCT07613567 · 486 participants (planned) · Start Jan 1, 2027 · Primary completion Dec 31, 2032
Drug: Cisplatin; Neoadjuvant chemoimmunotherapy and 1 more · For: Locally Advanced Cervical Carcinoma
Sites: Fuzhou, China
Qilu Pharmaceutical Co., Ltd.Industry
NCT07256782 · 444 participants (planned) · Start Oct 24, 2025 · Primary completion Oct 2026
Drug: QLC5508; QL1706 and 5 more · For: Advanced Solid Tumor
Sites: Shanghai, China
- A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular CarcinomaPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT07328009 · 350 participants (planned) · Start Jan 19, 2026 · Primary completion Jan 15, 2029
Drug: Lenvatinib; Regorafenib (BAY 73-4506) and 8 more · For: Hepato Cellular Carcinoma (HCC)
Sites: Shanghai, China
- FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRCPivotal-lookingNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07729605 · 270 participants (planned) · Start Jul 30, 2026 · Primary completion Dec 30, 2028
Drug: FOLFIRI + bevacizumab + QL1706; FOLFIRI + bevacizumab · For: Colorectal Cancer Metastatic; Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Sites: Guangzhou, China
- Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.Pivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT07829874 · 180 participants (planned) · Start Oct 26, 2026 · Primary completion Sep 20, 2028
Drug: QL1706 (Iparomlimab/Tuvonralimab); Lenvatinib · For: Biliary Tract Cancer (BTC)
Sites: Shanghai, China
- Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal CancerPivotal-lookingRecruiting
Shandong Cancer Hospital and InstituteAcademic, hospital or other
NCT07686640 · 180 participants (planned) · Start Aug 15, 2026 · Primary completion Jul 15, 2029
Drug: Consolidation treatment (With ICIs); Consolidation treatment (Without ICIs) · For: Local Advanced Rectal Cancer; Radiotherapy; Immunotherapy
Sites: Jinan, China
- Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer(Neo-Color)Pivotal-lookingRecruiting
Hebei Medical University Fourth HospitalAcademic, hospital or other
NCT06949111 · 128 participants (planned) · Start May 15, 2025 · Primary completion May 30, 2028
Drug: CAPOX; Capecitabine and 1 more · For: Colon Cancer
Sites: Shijiazhuang, China
- Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerPivotal-lookingRecruiting
Wenjin YinAcademic, hospital or other
NCT07180160 · 123 participants (planned) · Start Sep 25, 2025 · Primary completion Sep 2027
Drug: QL1706; CDK4/6 inhibitor and 1 more · For: Advanced Breast Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Case Report: Third-line QL1706, a bifunctional PD-1/CTLA-4 MabPair product, plus chemotherapy for primary small-cell neuroendocrine carcinoma of the ureter.
Li X, Meng Z, Liu Y, et al. · Front Pharmacol 2026
- Case Report: Brain metastasis from cervical cancer treated with multimodal therapy.
Liu J, Wen Y, Peng Y, et al. · Front Oncol 2026
- DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma.
Yang F, Tao W, Zhong Z, et al. · Future Oncol 2026
- Case Report: rapid clinical complete response to Iparomlimab and Tuvonralimab combined with radiotherapy and chemotherapy in a patient with MSS/pMMR locally advanced rectal cancer.
Wang J, Yang T, Zhou J, et al. · Front Oncol 2026
- Case Report: Iparomlimab and Tuvonralimab-based therapy for epithelioid malignant peritoneal mesothelioma: a three-case series.
Xu Z, Zhu L, Fang Y, et al. · Front Oncol 2026
- Iparomlimab and tuvonralimab in previously treated patients with cervical cancer.
Lou H, Zhou Y, Li D, et al. · Cell Rep Med 2026
Also in development for Small-cell Lung Cancer
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- ZG006Phase 38 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor
- GocatamigHPN328, MK-6070Phase 34 trials
Merck & Co. · Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer
- ZL-1310Phase 33 trials
Zai Lab (Shanghai) Co., Ltd. · Solid Tumors, Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma
- BL-M14D1Phase 32 trials
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- TuvonralimabPhase 32 trials
Qilu Pharmaceutical Co., Ltd. · Small-cell Lung Cancer, Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Atezolizumab followed by AtezolizumabPhase 31 trial
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- QL1604Phase 31 trial
Qilu Pharmaceutical Co., Ltd. · Small-cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.